These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy. Ferrera G, Cuccia M, Mereu G, Icardi G, Bona G, Esposito S, Marchetti F, Messier M, Kuriyakose S, Hardt K. Hum Vaccin Immunother; 2012 Mar; 8(3):355-62. PubMed ID: 22327497 [Abstract] [Full Text] [Related]
11. Immunogenicity and safety of a DTaP-IPV//PRP-T vaccine (Pentaxim) booster during the second year of life in Thai children primed with an acellular pertussis combined vaccine. Thisyakorn U, Pancharoen C, Chuenkitmongkol S, Ortiz E. Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):282-94. PubMed ID: 19323013 [Abstract] [Full Text] [Related]
12. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine. Sänger R, Behre U, Krause KH, Loch HP, Soemantri P, Herrmann D, Schmitz-Hauss E, Wolter J, Hoet B. Eur J Pediatr; 2007 Dec; 166(12):1229-36. PubMed ID: 17235521 [Abstract] [Full Text] [Related]
13. One-year post-primary antibody persistence and booster immune response to a fully liquid five-component acellular pertussis, diphtheria, tetanus, inactivated poliomyelitis, Haemophilus influenzae type b conjugate vaccine. Lin TY, Wang YH, Huang YC, Chiu CH, Lin PY, Chen CJ, Chavand P, Ortiz E. Int J Infect Dis; 2007 Nov; 11(6):488-95. PubMed ID: 17349809 [Abstract] [Full Text] [Related]
15. A modified vaccine reduces the rate of large injection site reactions to the preschool booster dose of diphtheria-tetanus-acellular pertussis vaccine: results of a randomized, controlled trial. Scheifele DW, Halperin SA, Ochnio JJ, Ferguson AC, Skowronski DM. Pediatr Infect Dis J; 2005 Dec; 24(12):1059-66. PubMed ID: 16371866 [Abstract] [Full Text] [Related]
18. Antibody persistence at 18-20 months of age and safety and immunogenicity of a booster dose of a combined DTaP-IPV//PRP∼T vaccine compared to separate vaccines (DTaP, PRP∼T and IPV) following primary vaccination of healthy infants in the People's Republic of China. Li RC, Li FX, Li YP, Hou QM, Li CG, Li YN, Chen FS, Hu XZ, Su WB, Zhang SM, Fang HH, Ye Q, Zeng TD, Liu TX, Li XB, Huang YN, Deng ML, Zhang YP, Ortiz E. Vaccine; 2011 Nov 21; 29(50):9337-44. PubMed ID: 22001281 [Abstract] [Full Text] [Related]